From Analysis:
Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular Denervation
What are the relative contributions of cell-autonomous motor neuron mechanisms versus non-cell-autonomous astrocyte and microglia mechanisms in mutant FUS-driven neuromuscular denervation in ALS — and do patient-derived chimeric co-culture systems with isogenic controls reveal independent glial contributions to NMJ dysfunction?
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["Cell-Autonomous vs Non-Cell-Autonomous
FUS Neuromuscular Denervation Mechanism"]
B["Perturbation-First Validation
Compartment-Specific FUS Targeting"]
C["Motor Neuron Intrinsic vs Glial Contribution
Conditional KO and Chimera Models"]
D["NMJ Stability Assessment
Synaptic Integrity Readout"]
E["Mechanism Resolution
Dominant Compartment Identification"]
F["ALS Therapeutic Strategy
Compartment-Matched Intervention Design"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Theorist position for analysis 687fb884-6d31-47c3-a83f-074bad980db6: Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular Denervation
Source basis: The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis (Nature Communications, 2025, DOI 10.1038/s41467-025-62351-3). The stored gap context says: NMJ denervation study identified myeloid cell involvement; cell-autonomous vs. non-cell-autonomous contributions of FUS mutations to NMJ pathology were not separated in the experimental design.
Primary hypothesis: mutant FUS effects split between m
Skeptic critique for analysis 687fb884-6d31-47c3-a83f-074bad980db6: Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular Denervation
The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: co-culture systems can exaggerate glial effects and underrepresent muscle and peripheral immune contributi
Domain expert assessment for analysis 687fb884-6d31-47c3-a83f-074bad980db6: Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular Denervation
The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect
{
"ranked_hypotheses": [
{
"title": "mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling as proximal driver in Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular Denervation",
"description": "mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling should produce a measurable proximal phenotype before late disease pathology. The decisive test is isogenic motor-neuron, astrocyte, and microglia chimeric co-cultures with NMJ formation and denervation readouts.",
No price history recorded yet
No clinical trials data available
No linked papers yet
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for ALS.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No knowledge graph edges recorded
neurodegeneration | 2026-04-27 | open
No comments yet. Be the first to comment!